The Lombardi Comprelnensive Cancer Center (Lombardi) leadership consists of Dr. Louis Weiner, Lombardi Director; Dr. Peter Shields, Lombardi Deputy Director; Dr. V. Craig Jordan, Scientific Director; Mr. Michael Vander Hoek, Associate Director for Administration and Planning; Dr. Jeanne Mandelblatt, Associate Director for Population Sciences; Dr. John Marshall, Associate Director for Clinical Research; Dr. Anton Wellstein, Associate Director for Basic Science Research; Dr. Lucile Adams-Campbell, Associate Director for Minority Health and Health Disparities Research; Dr. Stephen Byers, Associate Director for Shared Resources; Dr. Anna Riegel, Associate Director for Education. Dr. Weiner assumed his responsibilities as Lombardi's Director, and Chair of the Department of Oncology at Georgetown University Medical Center (GUMC) on January 1, 2008. He is an internationally recognized authority on monoclonal antibody engineering and therapy. As Lombardi Director, Dr. Weiner Is responsible for organizing and coordinating the activities of the six research programs of the Cancer Center Support Grant (CCSG), 12 shared resources, and all other activities of Lombardi. Dr. Shields Is an expert on gene-environment interactions in cancer risk, and as Deputy Director, Is responsible for operational oversight of Lombardi activities, working in concert with Mr. Vander Hoek, who oversees Administration and Planning. Dr. Jordan, who joins Lombardi on July 1, 2009, Is widely known for his seminal work with tamoxifen and for development of the SERM hypothesis; was recently elected to the National Academy of Sciences. As Scientific Director, he will be responsible for overseeing Lombardi's scientific portfolio, enhancing transdisciplinary research, and overseeing the disbursement of pilot funds. The Associate Directors provide oversight of Lombardi's programs, shared resources, education and administration/planning, with an emphasis on fostering transdisciplinary interactions. Dr. Marshall is an internationally recognized gastrointestinal cancer clinical researcher, who provides oversight of Lombardi's clinical and clinical research operations, and oversees the two Lombardi clinical programs. Dr. Wellstein oversees the two basic science programs, and Dr. Mandelblatt oversees the two population science programs. Dr. Adams-Campbell Is an epidemiologist and recently elected member of the Institute of Medicine who will coordinate and extend Lombardi's efforts to address disparities across Its research portfolio. Dr. Byers is an accomplished molecular biologist who oversees all aspects of Lombardi's shared resources. Dr. Riegel coordinates Lombardi's graduate programs. Drs. Weiner, Shields effort, Jordan, Marshall and Mr. Vander Hoek comprise the Senior Operational Leadership Team (SOLT), which meets weekly. SOLT members also attend monthly Associate Director meetings and Program Leader meetings. This leadership team is ideally structured to achieve Lombardi's mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-19
Application #
8375502
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$628,221
Indirect Cost
$539,910
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Rao, Guanhua; Pierobon, Mariaelena; Kim, In-Kyu et al. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2017) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother :
Vietsch, Eveline E; Graham, Garrett T; McCutcheon, Justine N et al. (2017) Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 218-219:39-50
Lynce, Filipa; Barac, Ana; Tan, Ming T et al. (2017) SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist 22:518-525
Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:
DeVito, Stephen; Woodrick, Jordan; Song, Linze et al. (2017) Mutagenic potential of hypoxanthine in live human cells. Mutat Res 803-805:9-16
Wang, Hongkun; Wang, Ying; Kota, Krishna K et al. (2017) Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder. Sci Rep 7:13493
Parodi, Daniela A; Greenfield, Morgan; Evans, Claire et al. (2017) Alteration of Mammary Gland Development and Gene Expression by In Utero Exposure to Cadmium. Int J Mol Sci 18:
Casero, David; Gill, Kirandeep; Sridharan, Vijayalakshmi et al. (2017) Space-type radiation induces multimodal responses in the mouse gut microbiome and metabolome. Microbiome 5:105

Showing the most recent 10 out of 997 publications